EA Pharma

Tokyo, Japan· Est. 2016

A Japanese specialty pharma focused on gastrointestinal and liver diseases, formed from the merger of Eisai and Ajinomoto's GI businesses.

eapharma.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese specialty pharma focused on gastrointestinal and liver diseases, formed from the merger of Eisai and Ajinomoto's GI businesses.

GastroenterologyHepatology

Technology Platform

Integrates traditional pharmaceutical R&D with Ajinomoto Group's proprietary amino acid science and technology, focusing on the role of amino acids in gut health and disease.

Opportunities

Opportunities include leveraging deep GI specialization to address high-unmet-need areas like IBD, developing novel amino acid-based therapeutics, and expanding its solution portfolio beyond drugs into nutritional and daily living support.

Risk Factors

Key risks include pipeline dependency on internal R&D success, competition from larger global pharma and biotech companies in GI, and potential constraints from being a subsidiary of two larger parent companies.

Competitive Landscape

Competes against global GI-focused players (e.g., Takeda in IBD, AbbVie) and diversified pharma with GI portfolios. Differentiates through exclusive disease focus, integrated amino acid technology platform, and a patient-centric 'hhc' philosophy inherited from Eisai.

More companies in Japan →